相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
REDUCE-IT USA Results From the 3146 Patients Randomized in the United States
Deepak L. Bhatt et al.
CIRCULATION (2020)
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies
Patrick R. Lawler et al.
EUROPEAN HEART JOURNAL (2020)
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
Samuel C. R. Sherratt et al.
CURRENT OPINION IN LIPIDOLOGY (2020)
Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation
Zhihuai Mo et al.
LIFE SCIENCES (2020)
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
R. Preston Mason et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus A Scientific Statement From the American Heart Association
Suzanne Arnold et al.
CIRCULATION (2020)
TRIGLYCERIDES AS A RISK FACTOR FOR CORONARY HEART DISEASE: WHAT MEASURE AND WHAT CUTOFF?
Ann Marie Navar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Eicosapentaenoic Acid Improves Hepatic Metabolism and Reduces Inflammation Independent of Obesity in High-Fat-Fed Mice and in HepG2 Cells
Kembra Albracht-Schulte et al.
NUTRIENTS (2019)
Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging
Takao Konishi et al.
CLINICAL CARDIOLOGY (2019)
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study)
Michael Miller et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques
Tomohito Sato et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
Nicholas A. Marston et al.
CIRCULATION (2019)
Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
Wenjun Fan et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
JoAnn E. Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FISHing for the Miracle of Eicosapentaenoic Acid
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2
Kelly Arps et al.
AMERICAN JOURNAL OF MEDICINE (2019)
Fish Oil Derived Omega 3 Fatty Acids Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity
Kailey Roberts Lee et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2019)
Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid
Samuel C. R. Sherratt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin
R. Preston Mason et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Heart Disease and Stroke Statistics-2018 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2018)
Eicosapentaenoic Acid-Enriched High-Density Lipoproteins Exhibit Anti-Atherogenic Properties
Nobuaki Tanaka et al.
CIRCULATION JOURNAL (2018)
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
Matthew Budoff et al.
CLINICAL CARDIOLOGY (2018)
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Om P. Ganda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker et al.
LANCET (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J. Nicholls et al.
CLINICAL CARDIOLOGY (2018)
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus
Louise Bowman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk
Peter P. Toth et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Systematic Review and Meta-Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in Patients with Peripheral Artery Disease
T. P. Singh et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2017)
Low Serum Levels of Eicosapentaenoic Acid and Docosahexaenoic Acid are Risk Factors for Cardiogenic Syncope in Patients with Brugada Syndrome
Shusuke Yagi et al.
INTERNATIONAL HEART JOURNAL (2017)
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
Tetsu Watanabe et al.
JOURNAL OF CARDIOLOGY (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
John R. Nelson et al.
POSTGRADUATE MEDICINE (2017)
Potential benefits of eicosapentaenoic acid on atherosclerotic plaques
J. R. Nelson et al.
VASCULAR PHARMACOLOGY (2017)
PCSK9 inhibitor access barriersissues and recommendations: Improving the access process for patients, clinicians and payers
Seth J. Baum et al.
CLINICAL CARDIOLOGY (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARY
Paul S. Jellinger et al.
ENDOCRINE PRACTICE (2017)
Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits
R. Preston Mason et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
History and future of omega-3 fatty acids in cardiovascular disease
Laurence S. Sperling et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
Matthew Budoff
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes
R. Preston Mason et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2016)
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Borge G. Nordestgaard
CIRCULATION RESEARCH (2016)
Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents
R. Preston Mason et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Donald M. Lloyd-Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Effect of n-3 fatty acids on the expression of inflammatory genes in THP-1 macrophages
Benedicte Allam-Ndoul et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis
Simon B. Pedersen et al.
JAMA INTERNAL MEDICINE (2016)
A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States
Sephy Philip et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel
Maciej Banach et al.
ARCHIVES OF MEDICAL SCIENCE (2015)
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
Kenneth M. Borow et al.
ATHEROSCLEROSIS (2015)
Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma
Ryo Nishio et al.
ATHEROSCLEROSIS (2014)
Eicosapentaenoic Acid Combined with Optimal Statin Therapy Improves Endothelial Dysfunction in Patients with Coronary Artery Disease
Kentaro Toyama et al.
CARDIOVASCULAR DRUGS AND THERAPY (2014)
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines
Jeffrey L. Anderson et al.
CIRCULATION (2014)
Low serum eicosapentaenoic acid level is a risk for ventricular arrhythmia in patients with acute myocardial infarction: a possible link to J-waves
Tomohide Endo et al.
HEART AND VESSELS (2014)
Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: A randomized, controlled study
Masayuki Doi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study
Kristian Laake et al.
BMC GERIATRICS (2014)
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
Eliot A. Brinton et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells
Anke Jaudszus et al.
JOURNAL OF LIPID RESEARCH (2013)
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Highly Purified Eicosapentaenoic Acid Increases Interleukin-10 Levels of Peripheral Blood Monocytes in Obese Patients With Dyslipidemia
Noriko Satoh-Asahara et al.
DIABETES CARE (2012)
Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function
Junko Sasaki et al.
ENDOCRINE JOURNAL (2012)
Identification and Structure Determination of Novel Anti-inflammatory Mediator Resolvin E3, 17,18-Dihydroxyeicosapentaenoic Acid
Yosuke Isobe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Resolvin E2 Formation and Impact in Inflammation Resolution
Sungwhan F. Oh et al.
JOURNAL OF IMMUNOLOGY (2012)
Omega-3 fatty acid supplementation and cardiovascular disease
Donald B. Jump et al.
JOURNAL OF LIPID RESEARCH (2012)
Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients
Ken Yamakawa et al.
CARDIOLOGY RESEARCH AND PRACTICE (2012)
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
Harold E. Bays et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Relationships between Plasma Fatty Acid Composition and Coronary Artery Disease
Hiroshige Itakura et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i)
J. C. Fruchart et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
In Vivo and In Vitro Inhibition of Monocyte Adhesion to Endothelial Cells and Endothelial Adhesion Molecules by Eicosapentaenoic Acid
Hideto Yamada et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Yasushi Saito et al.
ATHEROSCLEROSIS (2008)
Acute administration of fish oil inhibits triggered activity in isolated myocytes from rabbits and patients with heart failure
Hester M. Den Ruijter et al.
CIRCULATION (2008)
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
Michael Miller et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1β-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma
Akiko Kawashima et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2008)
Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects
Michiko Itoh et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation
Makoto Arita et al.
JOURNAL OF IMMUNOLOGY (2007)
Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes
Tomoya Mita et al.
ATHEROSCLEROSIS (2007)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
J Danesh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione
R Marchioli et al.
CIRCULATION (2002)
Blood levels of long-chain n-3 fatty acids and the risk of sudden death.
CM Albert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids
A Leaf
EUROPEAN HEART JOURNAL SUPPLEMENTS (2001)
Single point mutations affect fatty acid block of human myocardial sodium channel a subunit Na+ channels
YF Xiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
J Danesh et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
